L 739749

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596684

CAS#: 156511-34-1

Description: L 739749 is a CAAX peptidomimetic; a farnesyl-protein transferase inhibitor.

Chemical Structure

img
L 739749
CAS# 156511-34-1
Instruction

Theoretical Analysis

MedKoo Cat#: 596684
Name: L 739749
CAS#: 156511-34-1
Chemical Formula: C24H41N3O6S2
Exact Mass: 531.24
Molecular Weight: 531.720
Elemental Analysis: C, 54.21; H, 7.77; N, 7.90; O, 18.05; S, 12.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 739749; L-739749; L739749; L-739,749; L 739,749; L739,749;

IUPAC/Chemical Name: methyl (2R)-2-((2-amino-3-mercaptopropyl)amino)-2-(N-(((S)-3-methylpentyl)oxy)-3-phenylpropanamido)-4-(methylsulfonyl)butanoate

InChi Key: NMDIHBJSLHSAMQ-LDEFDFMYSA-N

InChi Code: InChI=1S/C24H41N3O6S2/c1-5-19(2)13-15-33-27(22(28)12-11-20-9-7-6-8-10-20)24(23(29)32-3,14-16-35(4,30)31)26-17-21(25)18-34/h6-10,19,21,26,34H,5,11-18,25H2,1-4H3/t19-,21?,24+/m0/s1

SMILES Code: CS(CC[C@@](C(OC)=O)(NCC(N)CS)N(OCC[C@@H](C)CC)C(CCC1=CC=CC=C1)=O)(=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 531.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dazy S, Damiola F, Parisey N, Beug H, Gandrillon O. The MEK-1/ERKs signalling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells. Oncogene. 2003 Dec 18;22(58):9205-16. PubMed PMID: 14681680.

2: Xu Y, Chiamvimonvat N, Vázquez AE, Akunuru S, Ratner N, Yamoah EN. Gene-targeted deletion of neurofibromin enhances the expression of a transient outward K+ current in Schwann cells: a protein kinase A-mediated mechanism. J Neurosci. 2002 Nov 1;22(21):9194-202. PubMed PMID: 12417644.

3: Bulus NM, Sheng HM, Sizemore N, Oldham SM, Barnett JV, Coffey RJ, Beauchamp DR, Barnard JA. Ras-mediated suppression of TGFbetaRII expression in intestinal epithelial cells involves Raf-independent signaling. Neoplasia. 2000 Jul-Aug;2(4):357-64. PubMed PMID: 11005570; PubMed Central PMCID: PMC1550294.

4: Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood. 2000 Jan 15;95(2):639-45. PubMed PMID: 10627474.

5: Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem. 1997 Jun 20;272(25):15591-4. PubMed PMID: 9188444.

6: Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res. 1997 Feb 15;57(4):708-13. PubMed PMID: 9044849.

7: Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol. 1997 Feb;17(2):862-72. PubMed PMID: 9001241; PubMed Central PMCID: PMC231813.

8: Fukazawa H, Nakano S, Mizuno S, Uehara Y. Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces. Int J Cancer. 1996 Sep 17;67(6):876-82. PubMed PMID: 8824562.

9: Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 1996 Jun 1;56(11):2626-32. PubMed PMID: 8653708.

10: James G, Goldstein JL, Brown MS. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4454-8. PubMed PMID: 8633088; PubMed Central PMCID: PMC39559.

11: Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol. 1995 Dec;15(12):6613-22. PubMed PMID: 8524226; PubMed Central PMCID: PMC230914.

12: Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995 Oct 15;55(20):4575-80. PubMed PMID: 7553632.

13: Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD, Oliff A. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem Suppl. 1995;22:145-50. Review. PubMed PMID: 8538192.

14: Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9141-5. PubMed PMID: 8090782; PubMed Central PMCID: PMC44763.

15: Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 1994 Jun;14(6):4193-202. PubMed PMID: 8196657; PubMed Central PMCID: PMC358785.